Corium International Inc (CORI) Expected to Post Quarterly Sales of $7.48 Million
Equities research analysts expect Corium International Inc (NASDAQ:CORI) to post sales of $7.48 million for the current quarter, Zacks reports. Two analysts have made estimates for Corium International’s earnings, with the highest sales estimate coming in at $7.57 million and the lowest estimate coming in at $7.39 million. Corium International posted sales of $6.97 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.3%. The firm is scheduled to issue its next quarterly earnings report on Monday, February 12th.
According to Zacks, analysts expect that Corium International will report full-year sales of $7.48 million for the current financial year, with estimates ranging from $31.97 million to $33.08 million. For the next fiscal year, analysts forecast that the company will report sales of $38.52 million per share, with estimates ranging from $38.21 million to $38.82 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Corium International.
A number of research analysts have weighed in on the company. Zacks Investment Research downgraded Corium International from a “hold” rating to a “sell” rating in a research note on Friday, December 29th. Needham & Company LLC raised their price target on Corium International from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, November 20th. ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Jefferies Group set a $10.00 price target on Corium International and gave the company a “buy” rating in a research note on Sunday, October 29th. Finally, HC Wainwright set a $14.00 price target on Corium International and gave the company a “buy” rating in a research note on Wednesday, December 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Corium International currently has a consensus rating of “Buy” and a consensus target price of $12.86.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in shares of Corium International by 33.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock worth $980,000 after acquiring an additional 22,285 shares during the period. California State Teachers Retirement System bought a new position in shares of Corium International during the 2nd quarter worth approximately $263,000. State Street Corp bought a new position in shares of Corium International during the 2nd quarter worth approximately $1,840,000. Stonepine Capital Management LLC bought a new position in shares of Corium International during the 2nd quarter worth approximately $3,085,000. Finally, EAM Investors LLC bought a new position in shares of Corium International during the 2nd quarter worth approximately $563,000. Institutional investors own 89.35% of the company’s stock.
Corium International (CORI) opened at $10.13 on Friday. The company has a current ratio of 7.04, a quick ratio of 6.80 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $358.86, a PE ratio of -6.07 and a beta of 1.26. Corium International has a fifty-two week low of $2.67 and a fifty-two week high of $12.32.
WARNING: “Corium International Inc (CORI) Expected to Post Quarterly Sales of $7.48 Million” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/06/corium-international-inc-cori-expected-to-post-quarterly-sales-of-7-48-million.html.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.